In addition to the search for a vaccine, drug companies are working to find effective treatments to reduce coronavirus symptoms and potentially prevent hospitalization. This week, pharmaceutical company Eli Lilly announced a breakthrough in their antibody research, as well as a potential treatment option with a drug commonly used to treat rheumatoid arthritis. For the latest from Eli Lilly, we spoke to Andrew Adams, Vice President of New Therapeutic Modalities and COVID-19 research at Eli Lilly.